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ORIGINAL RESEARCH ARTICLE
Routine detection and management of neurocognitive
impairment in HIV-positive patients in a UK centre
L J Haddow MRCP PhD*†, A Accoroni CPsychol†, J D Cartledge FRCP MD†‡, H Manji FRCP MD†‡, P Benn FRCP†
and R J C Gilson FRCP MD*†
*Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London; †Camden
Provider Services, Central and North West London NHS Foundation Trust; ‡University College London Hospitals NHS Foundation Trust,
London, UK
Summary: We estimated the burden of HIV-associated neurocognitive disorders (HAND) in a UK clinic. From a random sample,
and referrals to specialist services over one year (neurology, clinical psychology, hospital admissions), we determined whether
patients were diagnosed with HIV-associated dementia (HAD) and whether they reported symptoms suggesting neurocognitive
impairment (NCI). In the first sample, 2/150 (prevalence 1.3%; 95% confidence interval [CI] 0.2–4.7%) had documented HAD.
Eleven patients (7.3%; CI 3.7–12.7%) reported recent symptoms suggesting NCI; most of these individuals were diagnosed with a
psychiatric or substance-use disorder. Among specialist referrals with symptoms suggesting NCI, 11 were diagnosed with HAD from
a clinic population of 3129 individuals (annual incidence 0.4%; CI 0.2–0.6%). No patients with mildly symptomatic or asymptomatic
HAND were identified in either sample, suggesting that such patients remain undetected in current clinical practice. Evidence-based
screening for HAND in HIV clinics may be needed.
Keywords: HIV infection, AIDS dementia complex, HIV-associated neurocognitive disorder, asymptomatic neurocognitive
impairment, HIV-associated dementia, cross-sectional studies, prevalence
INTRODUCTION
The most recent British HIV Association (http://www.bhiva.
org/TreatmentofHIV1_2012.aspx) and European AIDS Clinical
Society (EACS) (http://www.europeanaidsclinicalsociety.org)
guidelines for the antiretroviral treatment of HIV-positive
adults now support the treatment of patients with symptomatic
neurocognitive impairment (NCI) – that is, both minor neuro-
cognitive disorder (MND) and HIV-associated dementia
(HAD) – regardless of CD4 count. Only the latter guidelines
discuss screening for HIV-associated neurocognitive disorders
(HAND) in routine HIV care, recommending a three-question
symptom questionnaire1 at HIV diagnosis, prior to starting anti-
retroviral therapy (ART) and at two-year intervals. It is difﬁcult
to determine the clinical impact of this new emphasis in the
guidelines, partly because of a lack of knowledge of the clinical
importance of mild-to-moderate HAND, low levels of detection
of such disorders, high rates of cognitive symptoms in those
with normal cognitive function and the absence of a strategy
for screening and testing in most clinics. We aimed to estimate
the current burden of NCI detected in routine HIV clinical prac-
tice in a large UK clinic.
METHODS
We conducted two retrospective cross-sectional surveys. In the
ﬁrst, a sample of 150 individuals was randomly selected from
a list of 3129 patients who attended the HIV clinic in the ﬁrst
half of both 2009 and 2010. We reviewed notes in April 2011
to determine whether patients had ever been diagnosed with
HAD, the equivalent diagnoses of AIDS dementia complex
(ADC) or HIV encephalopathy (HIVE) or milder HAND
(MND), and whether they had reported difﬁculties with cogni-
tive function in the 12-month period preceding the most recent
attendance. The diagnoses of HAD, according to two deﬁ-
nitions,2,3 and AIDS dementia complex4 purport to address
the same syndrome and have been shown to give similar diag-
nostic yield.5 The sample size gave 90% power to detect a 2.5%
or greater prevalence of the outcome. As well as identifying
clinicians’ contemporaneous observations of possible NCI,
documentation of incidental symptoms was interpreted by
researchers during the notes review process. Patients were
fully evaluated as indicated by clinical need. However, not all
symptomatic patients underwent sufﬁcient assessment of neu-
ropsychological function and activities of daily living to meet
current diagnostic criteria for HAND.2 Therefore, the diagnostic
label of MND may not necessarily have applied in this context.
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As there was no routine screening for HAND during the
data collection period, asymptomatic neurocognitive impair-
ment (ANI) was not recorded in the notes. Other data collected
included age, gender, current and nadir CD4 þ count, viral
load (VL), ART history, alcohol or drug abuse, relevant
medical history and neurological and psychiatric co-morbidity.
In the second survey, we reviewed the notes of all referrals
to an HIV neurology clinic, referrals with suspected NCI to
a specialist clinical psychology service for HIV and sexual
health-related problems, and admissions to an HIV inpatient
unit with symptoms of chronic cognitive impairment during
a similar 12-month period (August 2009 to July 2010). There
were no speciﬁc criteria for referral to these services, other
than the opinion of the patient’s HIV outpatient doctor or (in
the case of inpatient admissions) the admitting clinician. For
each patient, we recorded whether a diagnosis of HAD or a
related disorder had been made, as well as additional data as
above.
RESULTS
In the ﬁrst, random sample (n ¼ 150), median age was 43 years
(interquartile range [IQR] 38–49 years), 125 (83%) were men,
ethnicity was white (n ¼ 98, 65%), black African (n ¼ 20, 13%)
or other (n ¼ 32, 21%), route of infection was sex between
men (n ¼ 106, 71%), heterosexual sex (n ¼ 36, 24%), intravenous
drug use (n ¼ 2, 1.3%), vertical (n ¼ 1, 0.7%) or not known
(n ¼ 5, 3.3%), current CD4þ count was median 540 cells/mL
(IQR 400–720 cells/mL), nadir CD4þ was median 195 cells/
mL (IQR 130–280 cells/mL) and 129 patients (86%) were
taking ART, of whom 123 (95%) had VL ,50 copies/mL.
These characteristics were representative of the entire clinic
population during the same period. Median time since diagno-
sis was 8.8 years (IQR 5.3–14.5 years) and median duration of
ART was 6.6 years (IQR 3.3–11.1 years). Relevant co-morbidity
included depression (n ¼ 41, 27%), schizophrenia (n ¼ 1, 0.7%),
signiﬁcant substance misuse (n ¼ 14, 9%; including 8 individ-
uals with heavy alcohol use and 1 each using heroin, alcohol
and heroin in combination, g-hydroxybutyric acid [GHB],
crack cocaine, anabolic steroids and cannabis), hepatitis C
(n ¼ 10, 7%), and previous cerebral toxoplasmosis (n ¼ 2, 1.3%).
Of these 150 patients, two (1.3%; 95% conﬁdence interval [CI]
0.2–4.7%) had documented HAD (Figure 1), and no patients
had been diagnosed with MND or ANI. Eleven patients
(7.3%; 95% CI 3.7–12.7%), including the two with HAD, had
symptoms suggesting NCI within the last year of attendance.
Of these, six (55%) had signiﬁcant depressive symptoms, two
(18%) were attributed to efavirenz and one (9%) had possible
NCI that was confounded by depressive and psychological
problems when assessed neuropsychologically after the study
period.
In the second survey, there were 22 referrals to the HIV
neurology clinic, six referrals to clinical psychology and 14
admissions to the HIV inpatient unit with chronic cognitive dif-
ﬁculties, with or without focal neurological symptoms, during
a one-year period. One of the clinical psychology patients and
four of the hospitalized patients were also seen in neurology
clinic, and none were in the random sample of n ¼ 150
(above). Chronic cognitive symptoms reported by patients
referred to the neurology clinic were memory problems
(n ¼ 11), global cognitive impairment (n ¼ 9), impaired con-
centration (n ¼ 3) and word-ﬁnding difﬁculties (n ¼ 2), while
associated problems included motor signs and symptoms
(n ¼ 5), mood disturbance (n ¼ 3), altered behaviour (n ¼ 2),
balance/gait disturbance (n ¼ 2) and headache (n ¼ 1). Of the
ﬁve clinical psychology patients not seen by neurology clinic,
all complained of memory impairment and two complained
of difﬁculties with attention/concentration. The ward admis-
sions not seen by neurology clinic presented primarily with
global cognitive decline (n ¼ 10), behavioural disturbance
(n ¼ 3) or a systemic illness to which chronic cognitive impair-
ment was a secondary problem (n ¼ 1).
Thus there were 37 patients with suspected NCI requiring
specialist assessment and management from a clinic population
of approximately 3129 individuals (overall risk 1.2%; 95% CI
0.8–1.6%) in a one-year period (Figure 1). A ﬁnal diagnosis of
HAD or HIVE was made in six neurology referrals, ﬁve hospi-
tal admissions and no clinical psychology referrals, totalling
11 new cases in 3129 patients (0.4%; 95% CI 0.2–0.6%) in one
year. Common alternative diagnoses were anxiety and de-
pression (12 of 37 patients, 32%) and new or past opportunistic
infections (OIs) (5; 14%).
DISCUSSION
We have estimated a 1.3% prevalence of HAD in a small but
representative sample of patients currently attending a large
HIV clinic in the UK. Additionally, 7% of patients complained
of symptoms consistent with NCI during a one-year period.
Also in a one-year period, 1.2% of the clinic population was
referred to specialist services for the investigation and manage-
ment of chronic cognitive symptoms. Most of these symptoms
were not attributed to HAND, and the approximate annual
incidence of HAD detected through these referrals to specialist
services was 0.4%. Our estimates are in keeping with the rates
of HAD in recent studies using diverse diagnostic criteria in
different study populations in Europe and the USA.1–2,6–14
However, the near-absence of mild or moderate HAND
detected in routine care is striking when compared with
recent prevalence estimates of 10% and 28% for MND, 17%
for mild cognitive/motor disorder and 28% and 42% for
ANI.1,2,11 The UK may have different rates of HAND from
Figure 1 Prevalence estimates with 95% confidence intervals of
main reported diagnoses and complaints of interest. HAD,
HIV-associated dementia; NCI, neurocognitive impairment
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other regions due its demographic and clinical characteristics.
The HIV-positive population is ageing, with around a ﬁfth
of those accessing care aged 50 and above, has over 80% ART
coverage with over 90% of those achieving VL ,50 copies/
mL, and is culturally and ethnically diverse, and 30% of
newly diagnosed patients have CD4þ counts of ,200 cells/
mL at HIV diagnosis.15–17 There remains a need for accurate
UK and European estimates of the prevalence of all grades of
HAND, based on large, unbiased samples and complete assess-
ment according to current diagnostic criteria.2
We consider these estimates to reﬂect recent routine clinical
practice and ad hoc recording of patients’ symptoms, rather
than being a complete representation of the burden of cognitive
impairment in HIV-positive individuals. Despite these limit-
ations, our ﬁndings have implications for clinical practice. It
appears that most patients with MND and ANI will remain
undetected, while assessment of patients reporting symptoms
consistent with NCI will frequently detect patients with
anxiety, depression, OIs and drug and alcohol problems. In the
light of our ﬁndings, we have set up a multidisciplinary clinic
and referral pathway aiming to assess such patients, and will
be evaluating the use of the three-symptom questionnaire, as
advocated by EACS, in routine clinical practice. It is important
to detect patients withMNDbecause the rate of further cognitive
and functional decline in these patients, although poorly quanti-
ﬁed in the literature, may be between 16% and 52% over six
months to two years.2,5,18,19 Also, a study conducted in Italy
from 1996 to 2004 in a cohort with 41%prevalence of intravenous
drug use and 45%hepatitis C co-infection found a 1.4-fold higher
risk of virological failure in those who were neurocognitively
impaired at baseline, and a 2.9-fold higher rate of death in
those with NCI and virological failure compared with unim-
paired patients.20 We need further evidence on the accuracy of
screening tests for ANI andMND, the natural history and appro-
priate management of patients with mild-to-moderate HAND
and the beneﬁts of a screening strategy in various clinical
settings.
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